2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMOCompleted
Primary Objective- To explore the effects of NeoRecormon on well-trained cyclists and their cycling performance by exercise parameters. Secondary Objectives- To explore the effects of NeoRecormon on well-trained cyclists and their cycling…